Early breast cancer diagnosis model and early breast cancer diagnosis system

Abstract

The invention discloses an early breast cancer diagnosis model and an early breast cancer diagnosis system. The early breast cancer diagnosis model is as follows: Logit(P)=5.640+0.132*EXP(hsa_circ_0067772)+1.195*EXP(hsa_circ_0000512)-1.035*EXP (hsa_circ_0000091); and in the formula (1) P=1 / [1+e-Logit (P)] formula (2), hsa_circ_0067772, hsa_circ_00000512 and hsa_circ_0000091 are circRNAs derived from tumor cells in plasma, EXP is a relative expression value of each circRNAs, if the prediction probability P value is greater than 0.386, the subject is diagnosed as a breast cancer patient, and if the prediction probability P value is less than 0.386, the subject is diagnosed as not suffering from breast cancer. Not only can the relative blank of current clinical breast cancer liquid biopsy be filled, but also a new examination method is provided for patients who are inconvenient to perform breast imaging examination.

Description

technical field [0001] The invention relates to the field of medical detection of breast cancer, in particular to an early breast cancer diagnosis model and a diagnosis system. Background technique [0002] Breast cancer is the malignant tumor disease with the highest incidence rate and the second fatality rate among women in the world. Early diagnosis is the key to improve the prognosis of breast cancer patients. At present, the early diagnosis methods of breast cancer mainly rely on imaging techniques, including breast ultrasound, mammography and breast MRI. For liquid biopsy of breast cancer, traditional breast cancer circulating markers CEA, CA125, CA15-3, and CA19-9 have poor sensitivity and specificity for the diagnosis of breast cancer, and fail to provide effective evidence for early diagnosis of breast cancer. Therefore, circulating biomarker molecules with high sensitivity and specificity, as well as effective algorithms are needed to construct accurate breast can...

AI Technical Summary

Problems solved by technology

For liquid biopsy of breast cancer, traditional breast cancer circulating markers CEA, CA125, CA15-3, and CA19-9 have poor sensitivity and specificity for the diagnosis of breast cancer, and fail to provide effective evidence for early diagnosis of breast cancer. Therefore, circulating biomarker molecules with high sensitivity and specificity, as well as effective algorithms are needed to construct accurate breast cancer diagnostic models

Images